Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 17
Patient Selection and Sequencing of NSCLC ADCs
The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.
- Discuss which patients are potentially most suitable for:
- Dato-DXd
- Sacituzumab govitecan
- HER3-DXd
- With the potential approval of multiple ADCs in second line and beyond, how might these be sequenced in your clinical practice?